Last Updated on October 9, 2024 by The Health Master
Zydus Lifesciences has received tentative approval from the US Food and Drug Administration (USFDA) to market Sugammadex injection USP 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL), single-dose vials, according to a company statement.
Sugammadex is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery.
The drug will be manufactured at the group’s injectables manufacturing facility in Jarod, India, the statement added.
USFDA gives approval for Lenalidomide capsules
USFDA gives final approval for Cariprazine capsules
USFDA gives approval for this cancer drug
USFDA approves Venlafaxine, Pregabalin extended release tablets
USFDA gives nod for SPEVIGO To treat Generalized Pustular Psoriasis Flares
USFDA gives approval to Loperamide HCL and Simethicone Tablets
Drug alert: 45 out of 1330 samples declared as NSQ in August 2022
USFDA gives approval for Lenalidomide capsules
Panel recommends a separate legislation for Medical Devices
Govt adds 34 drugs in NLEM – National List of Essential Medicines
CDSCO classified Non-sterile, Non-powered, Hand-held Surgical Instruments
USFDA gives final approval for Cariprazine capsules
Role of IP in Pharmaceutical Industry
Drug repurposing: Advantages, Challenges and Opportunities
IPC adds 7 new Veterinary Monographs, 8 new Chemical Monographs to IP 2022
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
